Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Genevieve Marie Boland, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Genevieve Boland and Benchun Miao.
Connection Strength

0.820
  1. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021 06; 27(6):985-992.
    View in: PubMed
    Score: 0.242
  2. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 Apr 29.
    View in: PubMed
    Score: 0.061
  3. Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.058
  4. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020 07; 26(7):1114-1124.
    View in: PubMed
    Score: 0.057
  5. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res. 2019 11 15; 25(22):6852-6867.
    View in: PubMed
    Score: 0.054
  6. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Mol Syst Biol. 2019 03 11; 15(3):e8323.
    View in: PubMed
    Score: 0.052
  7. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.051
  8. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
    View in: PubMed
    Score: 0.051
  9. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 10; 24(10):1545-1549.
    View in: PubMed
    Score: 0.050
  10. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 10 01; 24(19):4771-4784.
    View in: PubMed
    Score: 0.049
  11. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.048
  12. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 10 05; 550(7674):133-136.
    View in: PubMed
    Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.